<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1">

The HALT HCM Study - Hypertrophic Cardiomyopathy In Cats


The HALT HCM Study is a blinded, randomized, placebo-controlled trial of TRIV202 in the management of ventricular hypertrophy associated with feline subclinical hypertrophic cardiomyopathy (HCM). The objective of the study is to determine the effectiveness and safety of 12 months’ dosing of once-weekly TRIV202 in feline subclinical HCM. The study will be conducted at 15-20 clinical sites in the United States, United Kingdom, and Europe that are experienced in treating cats with HCM. It will aim to enroll 300 cats.

HALT Study Graphic

Register For Trial Today!

We invite you to be a part of something truly meaningful - a pharmaceutical trial that has the potential to improve the lives of pets worldwide. By registering your beloved furry companion for our trial, you are taking a step towards a brighter and healthier future for them and countless other animals.

Fill In Your Details Here 👇

Free Downloads

RapaCat Overview Smaller Mockup

RAPACAT Feline Hypertrophic Cardiomyopathy Field Study

Multi-omic Feline Hypertrophic Cardiomyopathy Study Smaller Mockup

Multi-omic Feline Hypertrophic Cardiomyopathy Study In Laboratory Cats